From: MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
Patient characteristic | All patients | Patients with MRP3 IHC Data | Patients with MRP3 mRNA Data |
---|---|---|---|
# of Patients | 94 | 46 | 67 |
Gender: | Â | Â | Â |
   Male | 59 (63%) | 30 (65%) | 39 (42%) |
   Female | 35 (37%) | 16 (35%) | 28 (59%) |
Age: | Â | Â | Â |
   ≤ 45 years | 22 (23%) | 10 (22%) | 13 (19%) |
   >45 years | 72 (77%) | 36 (78%) | 54 (81%) |
KPS: | Â | Â | Â |
   90-100 | 51 (54%) | 23 (50%) | 38 (57%) |
   70 - 80 | 36 (38%) | 21 (46%) | 24 (36%) |
   50 - 60 | 5 (5%) | 2 (4%) | 3 (4%) |
   Unknown | 2 (2%) | 0 | 2 (3%) |
Extent of Resection: | Â | Â | Â |
   GTR | 75 (80%) | 34 (74%) | 55 (82%) |
   STR | 17 (18%) | 10 (22%) | 12 (18%) |
   Biopsy | 2 (2%) | 2 (4%) | 0 |
Post-operative Treatment: | Â | Â | Â |
   CPT-11 | 2 (2%) | 2 (4%) | 1 (1%) |
   CPT-11/Celebrex | 2 (2%) | 2 (4%) | 0 |
   Cyclophosphamide/Thalidomide | 1 (1%) | 1 (2%) | 0 |
   Gliadel | 4 (4%) | 2 (4%) | 2 (3%) |
   Gliadel→XRT | 7 (7%) | 5 (11%) | 7 (10%) |
   Gliadel→XRT/Temo | 4 (4%) | 2 (4%) | 2 (3%) |
   Mab I131-81C6 | 8 (9%) | 5 (11%) | 7 (10%) |
   Temozolomide | 3 (3%) | 2 (4%) | 2 (3%) |
   Temozolomide/CPT-11 | 1 (1%) | 0 | 1 (1%) |
   Temozolomide/Avastin | 1 (1%) | 0 | 1 (1%) |
   Vincristine/Cisplatin/Cyclophosphamide | 1 (1%) | 1 (2%) | 0 |
   XRT | 19 (20%) | 12 (26%) | 15 (22%) |
   XRT/Temo | 37 (39%) | 11 (24%) | 26 (39%) |
   None/Unknown | 4 (4%) | 1 (2%) | 3 (4%) |
Survival Status: | Â | Â | Â |
   Alive | 7 (7%) | 3 (7%) | 5 (7%) |
   Dead | 87 (93%) | 43 (93%) | 62 (93%) |
Available Data: | Â | Â | Â |
   RNA only | 48 (51%) | 0 | 48 (72%) |
   IHC only | 27 (29%) | 27 (59%) | 0 |
   RNA and IHC | 19 (20%) | 19 (41%) | 19 (28%) |